A randomized trial of multivitamin supplementation in children with tuberculosis in Tanzania by Mehta, Saurabh et al.
RESEARCH Open Access
A randomized trial of multivitamin
supplementation in children with tuberculosis in
Tanzania
Saurabh Mehta
1*, Ferdinand M Mugusi
2, Ronald J Bosch
3, Said Aboud
4, Anirban Chatterjee
5, Julia L Finkelstein
1,
Maulidi Fataki
6, Rodrick Kisenge
6 and Wafaie W Fawzi
7
Abstract
Background: Children with tuberculosis often have underlying nutritional deficiencies. Multivitamin
supplementation has been proposed as a means to enhance the health of these children; however, the efficacy of
such an intervention has not been examined adequately.
Methods: 255 children, aged six weeks to five years, with tuberculosis were randomized to receive either a daily
multivitamin supplement or a placebo in the first eight weeks of anti-tuberculous therapy in Tanzania. This was
only 64% of the proposed sample size as the trial had to be terminated prematurely due to funding constraints.
They were followed up for the duration of supplementation through clinic and home visits to assess
anthropometric indices and laboratory parameters, including hemoglobin and albumin.
Results: There was no significant effect of multivitamin supplementation on the primary endpoint of the trial:
weight gain after eight weeks. However, significant differences in weight gain were observed among children aged
six weeks to six months in subgroup analyses (n = 22; 1.08 kg, compared to 0.46 kg in the placebo group; 95% CI
= 0.12, 1.10; p = 0.01). Supplementation resulted in significant improvement in hemoglobin levels at the end of
follow-up in children of all age groups; the median increase in children receiving multivitamins was 1.0 g/dL,
compared to 0.4 g/dL in children receiving placebo (p < 0.01). HIV-infected children between six months and three
years of age had a significantly higher gain in height if they received multivitamins (n = 48; 2 cm, compared to 1
cm in the placebo group; 95% CI = 0.20, 1.70; p = 0.01; p for interaction by age group = 0.01).
Conclusions: Multivitamin supplementation for a short duration of eight weeks improved the hematological
profile of children with tuberculosis, though it didn’t have any effect on weight gain, the primary outcome of the
trial. Larger studies with a longer period of supplementation are needed to confirm these findings and assess the
effect of multivitamins on clinical outcomes including treatment success and growth failure.
Clinicaltrials.gov Identifier: NCT00145184
Introduction
Mycobacterium tuberculosis is one of the most success-
ful pathogens known to man-both in terms of its long-
evity as well as in its ability to infect and cause disease
in humans. Molecular genetics and genome sequencing
techniques estimate that early forms of M. tb were pre-
sent in East Africa at least 3 million years ago [1]; it
remains the single most common curable infectious
disease cause of mortality worldwide [2], despite the
availability of effective anti-tuberculous chemotherapy.
An estimated 250,000 children develop tuberculosis
(TB) and 100,000 die of it every year worldwide [3].
Age and immune status of the child are two major
determinants of progression to active TB after primary
infection-the risk is highest in very young (< 2 years of
age) and immunocompromised children [4,5]. Malnutri-
tion and HIV infection increase this risk further [4,6,7];
for example, it is estimated that only one out of ten
immunocompetent persons infected with TB develops
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HIV-infected persons infected with TB will develop
active TB every year [4].
Data from several studies indicate that TB is asso-
ciated with weight loss and protein and calorie malnu-
trition [8-12] and such poor nutritional status in TB
patients is a strong predictor of adverse events including
treatment failure and mortality [13-17]. Studies among
children without TB have shown a beneficial effect of
multiple micronutrient supplementation on growth
indices; for example, a meta-analysis showed that multi-
ple micronutrient interventions improved linear growth
(effect size: 0.09; 95% CI: 0.008, 0.17) [18]. In addition,
micronutrient supplementation can also lead to boosting
of the immune system, which may help improve the
response to TB treatment. There is limited data on the
prevalence of micronutrient deficiencies among children
with tuberculosis in resource-limited settings; however,
in a trial of multivitamin supplementation in Tanzania,
22% and 15% of children born to HIV-infected women,
who did not receive multivitamin supplementation, were
deficient in vitamins E (< 11.6 μmol/L) and B12 levels
(< 150 pmol/L), respectively [19]. However, there are no
studies of multivitamin supplementation among children
with TB. In our previous work, we have also shown the
benefits of maternal multivitamin (vitamins B-complex,
C, and E) supplementation on child morbidity and mor-
tality [20,21].
Therefore, we hypothesized that multivitamin supple-
mentation would improve weight gain, a predictor for
future growth and adverse clinical outcomes, in children
with TB. To test this hypothesis, we conducted a rando-
mized placebo-controlled trial among children with TB,
both with and without HIV infection, in Dar es Salaam,
Tanzania.
Materials and methods
Study Design and Population
This study was a randomized double-blind placebo con-
trolled trial among 255 children between the ages of six
weeks and five years with probable tuberculosis. A total
of 467 children aged six weeks to five years attending
the pediatric clinic between May 2005 and September
2007 at the Muhimbili National Hospital in Dar es Sal-
aam, Tanzania, were screened for signs and symptoms
of TB (Figure 1). The inclusion criteria comprised of
presenting with cough or wheezing for at least four
weeks, fever of unknown origin, painless swelling in a
group of cervical lymph nodes, loss of more than 10% of
maximum weight, failure to gain weight for two months,
or a history of household contact with a case of prob-
able/confirmed TB in the past six months, and these
children were diagnosed as having suspected TB.
Children who had received anti-TB treatment for more
than 4 weeks in the past year were not eligible.
A chest X-ray (Postero-Anterior view) was also
obtained and a tuberculin skin test (TST) was con-
ducted in all children. The TST used the standard
WHO-purified protein derivative (PPD) and it was read
after 48-72 hours. Children with a positive TST (indura-
tion greater than or equal to 10 mm in HIV-uninfected
and 5 mm in HIV-infected) or with a chest X-ray indi-
cative of TB (based on unequivocal lymphadenopathy or
miliary TB) were categorized as probable TB (n >2 7 5 )
and became eligible for enrolment in the study. The
chest X-rays were read both by the study radiologist and
the study pediatrician. Any discrepancies were resolved
by a joint review of the radiological findings.
Trained research assistants obtained informed consent
from the parents or guardians of the children in two
stages-first, for eligibility testing and the second for par-
ticipation in the trial.
Children with probable TB, written consent from par-
ent/guardian, and no intent to leave the Dar es Salaam
area over the next eight weeks were then randomly
assigned to receive daily multivitamin supplements or
placebo for the next two months (n = 255). An off-site
statistician generated the randomization sequence; a list
from 1 to 400 was prepared according to this randomi-
zation sequence in blocks of 20. At enrolment, each eli-
gible child was assigned to the next numbered bottle of
regimen at the site by the study staff. To minimize the
risk of unblinding, the regimen bottles, with no visual
difference between active regimen capsules and placebo
capsules, were received from the manufacturer (Nutriset,
France) without any identification; the study staff then
labeled the bottles with the patient’s initials and identifi-
cation number. Both the clinicians and the patients
were blinded to the study regimen, and the randomiza-
tion list was kept confidential by the statistician, with
the exception of the pharmaceutical company preparing
the blinded treatment.
Each multivitamin capsule contained vitamins B1 0.5
mg, B2 0.6 mg, Niacin 4 mg, B6 0.6 mg, Folate 130 μg,
B12 1 μg, C 60 mg, and E 8 mg. This composition was
selected based on the demonstrated benefits of maternal
multivitamin (vitamins B-complex, C, and E) supple-
mentation on child morbidity and mortality [20,21], par-
ticularly in subgroups of children born to women who
were immunologically or nutritionally compromised.
Zinc and iron, on the other hand, were excluded
because of concerns related to their supplementation,
particularly among HIV-infected populations [22,23].
The roles of zinc and iron need to be examined sepa-
rately rather than as part of a multi-nutrient regimen.
Similarly, there is limited data on the utility of nutrients
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therefore, they were not included in the study regimen.
Children younger than six months in both the treatment
and placebo groups received one capsule daily, whereas
children between 7-36 months of age received 2 capsules
daily, and children older than 36 months received three
capsules daily. The doses provided were in multiples (two
to five times) of the recommended dietary allowance as
have been used in our earlier studies. Ampoules of sterile
water to dissolve the contents of the capsule were also
given to the study participants. Both placebo and the
active regimen had a sweet taste when dissolved in sterile
water. In addition, all children received standard anti-TB
treatment, according to the guidelines of the National
Tuberculosis and Leprosy Control Programme of Tanza-
nia. The guidelines at the time of the trial recommended a
six-month course of anti-tuberculous drugs (Isoniazid 50
mg, Rifampicin 200 mg, Ethambutol 10-15 mg/kg, and
Pyrazinamide 20-30 mg/kg daily for 2 months, followed by
Isoniazid 50 mg and Rifampicin 200 mg daily for 4
months) using Directly Observed Therapy (DOT).
The institutional review boards at Harvard School of
Public Health, Boston, MA and Muhimbili University of
Health and Allied Sciences, Dar es Salaam, Tanzania
approved the study protocol.
Baseline Assessment
At randomization, a trained research assistant obtained
information on socio-economic and demographic char-
acteristics. Weight, height/length, head circumference,
mid-upper arm circumference (MUAC), and triceps
skin-fold thickness, were measured by a study nurse
according to standard methods. A physician also
obtained a complete medical history and conducted a
physical examination of the participating child at this
visit.
Figure 1 Trial Profile.
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All study subjects were followed up every two weeks;
the study nurse visited the child at home during weeks
2 and 6 and the child was seen at the study clinic during
weeks 4 and 8 of the study. During each visit, the study
nurse enquired about the health of the child during the
preceding two weeks and checked for compliance with
anti-TB therapy and the study regimen through direct
questioning of the parent/guardian and counting of the
capsules left. During the clinic visits, the study nurse
determined the anthropometric measurements, and a
physician examined the child.
Laboratory Methods
Venous blood was obtained from the participating chil-
dren at entry into the study and at the last visit at 8
weeks after starting anti-TB therapy. Complete blood
counts, including hemoglobin concentration, and albu-
min levels (using Roche Cobas Integra 400 plus analy-
zer) were determined for all participants. Total white
blood cell count was measured using a Beckman Coul-
ter AcT Diff II hematology analyzer and differential
white blood cell count was also determined automati-
cally. Absolute counts of T-cell subsets were measured
using the FACSCount system (Becton-Dickinson, San
Jose, CA).
HIV-1 (referred to as HIV henceforth) status was
assessed through a double ELISA for children older
than 18 months; any discrepancies were resolved using a
Western blot test. For children younger than 18 months
of age, HIV status was determined through Amplicor
H I V - 1D N AP C Rt e s tv e r s i o n1 . 5( R o c h eD i a g n o s t i c s ,
Branchburg, NJ).
Statistical Analysis
The study was designed to enroll 400 children with TB
and was powered (power = 80%) to detect a 27% differ-
ence in the primary endpoint of weight gain between
the supplemented and the placebo groups. Due to fund-
ing constraints, we could not extend the enrollment per-
i o dt oi n c r e a s es a m p l es i z eb e y o n d2 5 5 .T h ea t t a i n e d
sample size had adequate power to detect a 32.5% differ-
ence in weight gain between the supplemented and the
placebo groups. Intention to treat analyses for all end-
points was used.
Descriptive statistics were expressed as the median
with the first and third quartiles (interquartile range,
IQR) and non-parametric Wilcoxon test was used for
comparative statistics. Hodges-Lehmann 95% confidence
limits were used to express the effect size of the differ-
ence between the two groups. We also examined the
effect of the supplements within strata of age (younger
than six months, seven-36 months, and older than 36
months) and HIV status. Tests of interaction were based
on comparing the non-parametric estimate of the treat-
ment effect [24] between strata, using their standard
errors [25]. SAS version 9.2 (SAS Institute, Cary, NC)
was used for all the analyses.
Results
The baseline characteristics of the children enrolled in
the trial are presented by treatment arm in Table 1.
There were no significant differences between the two
treatment arms. The median age was 18 months in both
the placebo and the supplement groups. Forty seven
percent and 44% of the children enrolled were females
in the placebo and the supplemented groups, respec-
tively. Twenty nine percent of the children in the pla-
cebo group and 39% in the supplemented group were
HIV-infected. Only 3 children out of the 146 who had
available gastric aspirate or sputum for culture had
mycobacteria isolated in the sample.
There were no significant differences in weight gain or
changes in height, MUAC, head circumference, and tri-
ceps skin-fold thickness between the two groups during
follow-up (Table 2). Children in both the placebo and
the supplement groups gained a median of 0.84 kg in
the two months since starting anti-TB therapy (n = 237;
95% CI = -0.15, 0.18; p = 0.82). However, there was sig-
nificant effect modification by age group (p < 0.01); chil-
dren younger than six months of age who received
multivitamins gained a median of 1.08 kg, compared to
0.46 kg gained by children receiving placebo in that age
group (95% CI = 0.12, 1.10; p = 0.01).
There was no difference in the gain in length/height
during follow-up between the two groups (p = 0.53).
However, HIV-infected children between the ages of 6
months and 3 years gained a median of 2 cm when
receiving multivitamins, compared to 1 cm when receiv-
ing placebo (n = 48; 95% CI = 0.20, 1.70; p = 0.01; p for
interaction by age group = 0.01).
The median increase in MUAC was 1.0 cm in the pla-
cebo group and 0.8 cm in the supplement group (p =
0.61). Head circumference increased by a median of 0.5
cm in both the placebo and the supplement groups (p =
0.86). The change in triceps skin-fold thickness over the
period of follow-up was an 1.1 cm increase in the pla-
c e b og r o u pa n d0 . 7c mi n c r e a s ei nt h es u p p l e m e n t
group (p = 0.37).
There was no difference in the clearance of chest x-
ray or mortality in the two treatment arms. 199 children
had a chest X-ray available at the end of follow-up and
100 of them showed complete resolution. 13 children
died during the course of the trial.
There was no significant difference in the hemoglobin
levels in children in the placebo and supplement groups
at baseline (Table 3); however, a significant difference
was noted by the end of follow-up (n = 223) with the
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increase in the hemoglobin levels by a median of 1.0 g/
dL, compared to children in the placebo group (median
of 0.4 g/dL; p < 0.01). In subgroup analyses by sex, this
effect on hemoglobin was not statistically significant in
female children (p = 0.11).
No significant differences were observed in changes in
albumin, and CD4, CD8, and CD3 T-cell counts
between the placebo and the supplemented groups over
follow-up. However, significant effect modification by
age group was observed in CD8 T-cell counts (p =
0.01). Children 3 years and older showed a median
increase in CD8 T-cell counts of 135 when receiving
multivitamins, compared to a median decrease of 158
o b s e r v e di nc h i l d r e ni nt h esame age group receiving
placebo (95% CI = 37.00, 1029.00; p = 0.03).
On restricting the analyses to only the 87 HIV-
infected children, a similar relationship was observed for
hemoglobin as in the overall cohort. Children in the
supplemented group gained a median of 1.2 g/dL of
hemoglobin compared to no change in the median of
the placebo group (p < 0.01).
Discussion
We found that daily multivitamin supplementation in
children with TB in a resource-limited setting resulted
Table 1 Baseline Characteristics of children with TB randomized in the trial (n = 255)
Variable Placebo (n = 127) Multivitamins (n = 128)
Age, in years, Median (IQR)
a 1.50 (0.83, 2.42) 1.54 (0.79, 2.92)
Shillings
b spent on food per household per day, Median (IQR)
a 2500.00
(2000.00, 3000.00)
2000.00
(2000.00, 3000.00)
Age categories, n (%)
≤ 6 months 9 (7.09%) 13 (10.16%)
6 months to ≤ 3 years 93 (73.23%) 85 (66.40%)
> 3 years 25 (19.68%) 30 (23.44%)
Females, n (%) 60 (47.24%) 56 (43.75%)
HIV-infected, n (%) 37 (29.13%) 50 (39.06%)
≤ 6 months 4 (44.44%) 4 (30.77%)
6 months to ≤ 3 years 23 (24.73%) 29 (34.12%)
> 3 years 10 (40.00%) 17 (56.67%)
Marital Status of Mother, n (%)
Single 15 (11.81%) 15 (11.72%)
Married 81 (63.78%) 70 (54.69%)
Divorced 2 (1.58%) 3 (2.34%)
Cohabiting 20 (15.75%) 32 (25.00%)
Separated 6 (4.72%) 7 (5.47%)
Widowed 3 (2.36%) 1 (0.78%)
Mother Literate, n (%) 114 (89.76%) 117 (91.41%)
Mother’s Occupation, n (%)
Housewife 75 (59.05%) 71 (55.47%)
Small business/Farm/Informal Income 41 (32.28%) 42 (32.81%)
Business woman 3 (2.36%) 6 (4.69%)
Public House/Restaurant 1 (0.79%) 1 (0.78%)
Professional (Nurse/Teacher) 2 (1.58%) 2 (1.56%)
Skilled Office Work 0 (0.00%) 2 (1.56%)
Unskilled Employment 3 (2.36%) 4 (3.13%)
Other 2 (1.58%) 0 (0.00%)
Meat or fish consumption, n (%)
Never/Less than once per month 2 (1.61%) 4 (3.15%)
Sometimes/1-3 times per month 13 (10.48%) 11 (8.66%)
About once per week 33 (26.61%) 31 (24.41%)
2-4 times per week 69 (55.65%) 77 (60.63%)
Everyday/5-7 times per week 7 (5.65%) 4 (3.15%)
Admitted to the Hospital, n (%) 21 (16.54%) 21 (16.41%)
a IQR: Inter-Quartile Range
b 1000 Tanzanian Shillings ≈ 1 US Dollar at the time of the trial
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months of follow-up in all age groups and irrespective
of HIV status. However, there was no effect of the sup-
plement on albumin levels and growth indices, including
weight, length/height, mid-upper arm circumference,
head circumference, and triceps skin-fold thickness in
the overall cohort. In subgroup analyses, significant
weight gain among the youngest children (six weeks to
six months) was observed. The results were similar in
children also co-infected with HIV; however, these chil-
dren had a significantly higher increase in height if
between the ages of 6 months and three years.
There have been no earlier studies of multivitamin
supplementation among children with TB. However,
similar beneficial effects of supplements on hemoglobin
levels have been obtained with micronutrient supple-
m e n t a t i o ni nc h i l d r e ni no t h e rp a r t so ft h ew o r l d .A
recent review by Allen et al reported that multiple
micronutrient supplementation leads to a significant
increase in hemoglobin in children (effect size 0.39; 95%
CI 0.25, 0.53) [26]. A pooled analysis used data from
intervention trials in Indonesia, Peru, South Africa, and
Vietnam among 1134 infants who had been randomized
to either a placebo, weekly multiple micronutrient sup-
plement (including vitamins A, D, E, K, C, B-1, B-2, B-6,
and B-12, niacin, folate, iron, zinc, copper, and iodine),
daily multiple micronutrient supplement, or daily iron
supplements. The daily micronutrient supplement was
found to be the most effective in controlling anemia and
iron deficiency [27].
The results are biologically plausible since the vita-
mins included in the supplement may lead to better
hematologic status through several mechanisms [28].
For example, vitamin C improves intestinal absorption
of iron and may also enhance mobilization of iron stores
and riboflavin is necessary for the synthesis of the globin
component of hemoglobin.
The effects on growth indices have comparatively been
less consistent; the review by Allen et al reported small
yet statistically significant improvements in length/
Table 2 Effect of multivitamin supplementation on anthropometric measurements
Outcome Time Point (n)
a Placebo Multivitamins Hodges-Lehmann p-value
c
Median (IQR)
b Median (IQR)
b 95% CI
(Multivitamin-Placebo)
Weight, kg
Baseline (255) 7.95 (6.20, 10.75) 8.48 (6.52, 10.81) (-1.15, 0.36) 0.31
Intermediate (245) 8.52 (6.84, 11.43) 9.38 (7.08, 11.81) (-0.35, 1.28) 0.30
Final (237) 9.01 (7.20, 12.02) 9.80 (7.74, 11.94) (-0.38, 1.31) 0.28
Change (237) 0.84 (0.45, 1.30) 0.84 (0.51, 1.30) (-0.15, 0.18) 0.82
Height, cm
Baseline (255) 74.00 (67.50, 87.00) 77.50 (68.00, 86.55) (-4.60, 1.00) 0.28
Intermediate (245) 75.00 (68.00, 87.00) 77.45 (69.40, 88.00) (-1.00, 4.80) 0.23
Final (236) 76.00 (69.00, 88.20) 79.00 (70.00, 88.30) (-1.00, 5.00) 0.24
Change (236) 1.10 (0.50, 2.00) 1.50 (0.50, 2.50) (-0.20, 0.50) 0.53
MUAC, cm
Baseline (255) 13.00 (11.20, 14.00) 13.00 (11.90, 14.25) (-0.70, 0.25) 0.35
Intermediate (245) 13.50 (12.00, 14.50) 14.00 (12.50, 15.00) (-0.10, 0.80) 0.18
Final (237) 13.80 (12.55, 15.00) 14.00 (12.70, 15.00) (-0.30, 0.50) 0.56
Change (237) 1.00 (0.20, 1.50) 0.80 (0.20, 1.50) (-0.35, 0.20) 0.61
Head Circumference, cm
Baseline (254) 45.50 (43.00, 48.00) 46.00 (43.50, 48.00) (-1.00, 0.50) 0.58
Intermediate (245) 46.00 (43.80, 48.00) 46.45 (44.00, 48.00) (-0.50, 1.00) 0.59
Final (236) 46.00 (44.10, 48.50) 46.50 (44.40, 48.50) (-0.50, 1.00) 0.58
Change (235) 0.50 (0.00, 1.00) 0.50 (0.00, 1.00) (-0.20, 0.25) 0.86
Triceps skin-fold thickness, cm
Baseline (255) 6.20 (5.20, 7.90) 6.15 (5.15, 8.00) (-0.60, 0.40) 0.55
Intermediate (245) 7.10 (5.60, 8.20) 7.20 (6.10, 8.95) (-0.20, 0.90) 0.25
Final (237) 7.50 (6.20, 8.60) 7.20 (6.00, 8.90) (-0.70, 0.40) 0.61
Change (237) 1.05 (-0.20, 2.10) 0.70 (-0.30, 1.90) (-0.70, 0.20) 0.37
a Intermediate is at 4 weeks follow-up; Final at 8 weeks follow-up; Change between the final and the baseline measurement
b IQR: Interquartile Range
c p-value based on Wilcoxon 2-group comparison
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ple micronutrients [26]. On the other hand, the pooled
analysis cited above found that infants receiving a daily
micronutrient supplement had significantly greater
weight gain, whereas there were no differences in height
gain [27]. In another meta-analyses of effects of micro-
nutrient interventions on growth of children under five
years of age, Ramakrishnan et al. found that multiple
micronutrient interventions improve linear growth only
and had no effect on weight gain [18]. Additionally, a
few studies of multiple micronutrient supplementation
in adults with tuberculosis have also been equivocal in
their results on weight gain. For example, a study in
Mwanza, Tanzania, found that multiple micronutrient
supplementation (vitamins A, B-complex, C, D, and E,
selenium, copper, and zinc) for the first two months of
TB treatment led to reduced weight gain among the
HIV-infected TB patients; the HIV-uninfected TB
patients demonstrated a non-significant increase in
weight at the end of follow-up [29].
Several studies have found that serum albumin is
lower among patients with TB [13,14,30-35]; however,
there are no studies assessing the effect of multivitamin
supplementation on albumin levels among children with
TB that we can directly compare our results to. The
increase in albumin in all children observed in this trial
is probably a response to adequate treatment for TB.
The main limitations of our trial were the small sam-
ple size and a short period of supplementation and fol-
low-up; this could have led us to miss a beneficial effect
of multivitamins on growth indices in the overall cohort,
the primary outcome. The trial also was not designed to
measure effects of multivitamins in subgroups such as
those defined by age or HIV status; therefore, the find-
ings of weight gain among the youngest children or
height differences among HIV infected children between
the ages of 6 months and 3 years cannot be treated as
conclusive. Further, it is possible that we may have
included children with other diseases, as TB diagnosis
was not optimal. It is also possible that the nutrients
such as zinc and vitamin D that were not included in
our supplement are more essential for growth. The
results of this trial should be generalizable to children
with TB, with or without HIV co-infection, in most
resource-limited settings.
The multivitamin supplement that we used has the
potential to have several beneficial effects including on
immune function in growing children, particularly those
with TB as they may have several underlying micronu-
trient deficiencies, including those of vitamins B-
Table 3 Effect of multivitamin supplementation on laboratory parameters
Outcome Time Point (n)
a Placebo Multivitamins Hodges-Lehmann p-value
c
Median (IQR)
b Median (IQR)
b 95% CI
(Multivitamin-Placebo)
Hemoglobin, g/dL
Baseline (251) 8.70 (7.70, 9.80) 8.40 (7.40, 9.50) (-0.20, 0.60) 0.28
Final (225) 9.40 (8.45, 10.25) 9.60 (8.70, 10.60) (0.00, 0.70) 0.05
Change (223) 0.40 (-0.30, 1.40) 1.00 (0.30, 2.30) (0.30, 1.00) 0.0001
Albumin, g/L
Baseline (253) 33.95 (29.90, 38.90) 34.00 (29.80, 39.10) (-1.70, 1.70) 0.92
Final (232) 40.20 (36.30, 42.90) 38.90 (33.80, 42.50) (-2.70, 0.10) 0.08
Change (231) 4.55 (0.10, 9.60) 3.40 (0.60, 7.00) (-2.60, 0.60) 0.21
CD4, cells/μL
Baseline (242) 1592.50 (1099.00, 2254.00) 1351.50 (803.00, 2208.50) (-410.00, 45.00) 0.11
Final (212) 1507.50 (1038.50, 2011.50) 1410.50 (782.50, 1904.50) (-373.00, 71.00) 0.19
Change (207) -63.00 (-506.00, 240.00) -59.50 (-448.00, 261.00) (-204.00, 140.00) 0.73
CD8, cells/μL
Baseline (242) 1233.00 (902.00, 2230.00) 1492.00 (988.00, 2624.00) (-16.00, 450.00) 0.06
Final (212) 1328.00 (921.50, 2208.50) 1506.50 (1039.00, 2742.00) (-98.00, 389.00) 0.24
Change (207) -130.00 (-489.00, 394.00) -77.50 (-735.00, 432.00) (-322.00, 193.00) 0.68
CD3, cells/μL
Baseline (242) 3317.50 (2423.00, 4616.00) 3593.50 (2430.00, 5211.50) (-311.00, 590.00) 0.53
Final (212) 3176.00 (2269.00, 4676.50) 3540.50 (2871.00, 4614.50) (-154.00, 681.00) 0.21
Change (207) -223.00 (-1149.00, 724.00) -324.00 (-1179.00, 889.00) (-519.00, 466.00) 0.89
a Final at 8 weeks follow-up; Change between the final and the baseline measurement
b IQR: Interquartile Range
c p-value based on Wilcoxon 2-group comparison
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Page 7 of 9complex, C, and E [36]. These nutrients are extensively
involved in the immune system and its ability to fight
infectious diseases such as TB. For example, the B-vita-
mins are involved in increasing lymphocyte production,
cell-mediated cytotoxicity, delayed-type hypersensitivity
responses, and antibody production [37,38]. Vitamin C
helps improve T- and B-lymphocyte proliferative
responses and reduces the concentration of proinflam-
matory cytokines [39-41]. Vitamin E is responsible for
improving delayed type hypersensitivity skin response,
increasing IL-2 production, neutrophil phagocytosis,
lymphocyte proliferation, and antibody response to T-
cell dependent vaccines, and reducing production of
inflammatory cytokines such as TNF- a and IL-6
[42,43]. However, we did not observe an association
between immune markers such as CD4, CD8, and CD3
T-cell count with multivitamin supplementation, except
for children older than 3 years of age. We are not aware
of any known age-specific effects of vitamins on CD8
cells in this age group that may explain this finding.
In conclusion, multivitamin supplementation had no
effect on weight gain, the primary outcome of the trial.
However, supplementation, even for a short period of
eight weeks, improved the hematological profile of all
children with TB and led to significant weight gain
amongst the youngest patients (n = 22; age six weeks to
six months). It is possible that older children need even
greater doses of such nutrients to demonstrate an effect
and for longer periods of time. The impact of multivita-
min supplementation on other parameters such as treat-
ment outcomes needs to be assessed in larger trials with
a longer period of supplementation. If proven to be effi-
cacious, multivitamin supplementation could represent
an inexpensive adjunct to anti-tuberculous therapy, par-
ticularly in resource-limited settings.
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